Probiotics and inflammatory bowel disease: an umbrella meta-analysis of relapse, recurrence, and remission outcomes.

Background: Inflammatory Bowel Diseases (IBD) encompass chronic inflammatory conditions such as ulcerative colitis and Crohn's disease. This umbrella meta-analysis investigates the efficacy of probiotic supplementation in reducing relapse, recurrence, and maintaining remission in IBD patients. Metho...

Descripción completa

Detalles Bibliográficos
Publicado en:Nutrition & Metabolism Vol. 22; no. 1; pp. 1 - 16
Autores principales: Liu, Wei, Zhang, Shengbo, Dong, Changzheng, Lv, Xia, Zheng, Ximin, Zhao, Wei, Jamali, Mehrdad, Abedi, Ranasadat, Saedisomeolia, Ahmad
Formato: meta analysis research systematic review tables/charts Journal Article
Publicado: BioMed Central 9/30/2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=188356923&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 188356923
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        17437075
        1CYX
      jtl: Nutrition & Metabolism
      issn: 17437075
      maglogo: N
    pubinfo:
      dt: 9/30/2025
      vid: 22
      iid: 1
      pid: 24147
      pub: BioMed Central
    artinfo:
      ui:
        188356923
        188356923
        188356923
        10.1186/s12986-025-01002-2
        188356923
      ppf: 1
      ppct: 15
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Probiotics and inflammatory bowel disease: an umbrella meta-analysis of relapse, recurrence, and remission outcomes.
      aug:
        au:
          Liu, Wei
          Zhang, Shengbo
          Dong, Changzheng
          Lv, Xia
          Zheng, Ximin
          Zhao, Wei
          Jamali, Mehrdad
          Abedi, Ranasadat
          Saedisomeolia, Ahmad
        affil: https://ror.org/05jb9pq57 Department of Gastrointestinal Surgery, People's Hospital Affiliated to Shandong First Medical University, No. 001, Xuehu Street, Changshao North Road, Laiwu District, 271100, Jinan, China
      sug:
        subj:
          Inflammatory Bowel Diseases Drug Therapy
          Probiotics Therapeutic Use
          Dietary Supplementation
          Recurrence
          Disease Remission
          Treatment Outcomes Evaluation
          Drug Efficacy Evaluation
          Human
          Systematic Review
          Meta Analysis
          PubMed
          Colitis, Ulcerative
          Crohn Disease
          Treatment Effect Heterogeneity
          Embase
          Maximum Likelihood
          Effect Size
          Correlation Coefficient
          Quality Assessment
          Relative Risk
          Confidence Intervals
          Publication Bias
          Data Analysis Software
          Descriptive Statistics
          Funding Source
      ab: Background: Inflammatory Bowel Diseases (IBD) encompass chronic inflammatory conditions such as ulcerative colitis and Crohn's disease. This umbrella meta-analysis investigates the efficacy of probiotic supplementation in reducing relapse, recurrence, and maintaining remission in IBD patients. Methods: We systematically searched PubMed, Scopus, and Web of Science up to November 2024 for meta-analyses evaluating probiotics in IBD. A random-effects model calculated pooled effect sizes. The methodological quality of included reviews was assessed using AMSTAR 2. Publication bias was evaluated through funnel plots, Egger's and Begg's tests, and corrected by trim-and-fill when appropriate. Results: Twenty meta-analyses including 46 datasets were analyzed. Probiotics significantly reduced relapse risk compared to placebo (RR = 0.55; 95% CI, 0.22–0.88), but showed no significant effect compared to mesalazine. No consistent benefit was found for remission or recurrence; however, recurrence risk was reduced after correction for publication bias (RR:0.74;95%CI:0.51–0.97, P < 0.05). Subgroup analyses suggested greater benefit with lower probiotic doses (≤ 10¹⁰ Colony-Forming Units/day) and longer supplementation durations (≥ 8 weeks) regarding to relapse rate, although strain-specific effects could not be clarified. Conclusion: Probiotic supplementation appears effective in reducing relapse compared to placebo, but shows no advantage over mesalazine and demonstrates benefit for recurrence only after adjusting for publication bias. These findings highlight a potential role for probiotics in IBD management, but interpretation should be cautious given the high heterogeneity and substantial overlap among included meta-analyses. Further high-quality, non-overlapping meta-analyses and randomized controlled trials are needed to determine the most effective probiotic regimens.
      pubtype: Academic Journal
      doctype:
        meta analysis
        research
        systematic review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N